N/A
N=300
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
SARS-CoV 2 · COVID-19
Bottom Line
View on ClinicalTrials.gov: NCT04383587 ↗Enrolled (actual)
300
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Number of Participants With COVID-19 Antibodies — 8; 284 Participants — p=>0.18
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Serologic testing (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With COVID-19 Antibodies |
8; 284 | >0.18 |
| SECONDARY Ability to Predict Immune Status/Antibody Positivity |
26; 1 | — |
Summary
The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years old.
- Mayo Clinic employee in procedural and surgical area.
- Suspected COVID-19 exposure.
- Completed PCR test twice with negative results.
Exclusion Criteria
- Refusal to participate in this study.
Data sourced from ClinicalTrials.gov (NCT04383587). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.